2 Min Read
The initial public offering (IPO) of Sai Life Sciences Ltd opened for subscription on Wednesday. The ₹3,043-crore mainboard issue was booked 62% on the first day of bidding, the NSE data till 4:30 PM showed.
The IPO is open for subscription from December 11 to December 13.
The portion reserved for retail investors was subscribed 8% as of 4:30 PM, while that for non-institutional investors also saw tepid subscription of nearly 6%. The overall subscription has been led by institutional investors, who subscribed to 2.07 times the shares on offer so far.
Here’s a look at the latest GMP, price band, offer size and other important details about the Sai Life Sciences IPO for the investors interested in participating in the bidding process.
Sai Life Sciences IPO GMP
Shares of Sai Life Sciences were trading at a premium of ₹28 in the grey market, at 4:30 PM on December 11, as per reports. The latest GMP for Sai Life Sciences IPO indicates an expected listing price of ₹577 per share with a potential listing gain of 5%.
As the GMP is an indicative price, the investors should take into account the company’s fundamentals, industry dynamics and associated risks before submitting their bids. The GMP, or grey market premium, is not an official price for the IPO stock but it gives an estimated listing price of the stock.
Sai Life Sciences, a Hyderabad-based contract research and manufacturing services (CRAMS) provider, aims to raise ₹3,042.62 crore through its IPO. The total offer size is a combination of a fresh issue of shares worth ₹950 crore and an offer-for-sale (OFS) portion of ₹2,092.62 crore.
The IPO price band has been fixed at ₹522-549 per share. The minimum investment for the retail investors is ₹14,823 for at least a single lot size of 27 shares.
The IPO allotment status is expected to be finalised by Sai Life Sciences on December 16. Shares of Sai Life Sciences Ltd will make their debut on the stock exchanges on December 18.
Sai Life Sciences specialises in offering end-to-end solutions for small molecule drug development and manufacturing, serving global pharmaceutical and biotech companies. The company reported a net profit of ₹28.01 crore in the six months ended September 2024, marking a turnaround from a net loss in the previous year.
Sai Life Sciences offers exposure to the growing pharmaceutical CRAMS sector, driven by global demand for innovative drug solutions.
| Company | Value | Change | %Change |
|---|
The IPO is open for subscription from December 11 to December 13.
The portion reserved for retail investors was subscribed 8% as of 4:30 PM, while that for non-institutional investors also saw tepid subscription of nearly 6%. The overall subscription has been led by institutional investors, who subscribed to 2.07 times the shares on offer so far.
Here’s a look at the latest GMP, price band, offer size and other important details about the Sai Life Sciences IPO for the investors interested in participating in the bidding process.
Sai Life Sciences IPO GMP
Shares of Sai Life Sciences were trading at a premium of ₹28 in the grey market, at 4:30 PM on December 11, as per reports. The latest GMP for Sai Life Sciences IPO indicates an expected listing price of ₹577 per share with a potential listing gain of 5%.
As the GMP is an indicative price, the investors should take into account the company’s fundamentals, industry dynamics and associated risks before submitting their bids. The GMP, or grey market premium, is not an official price for the IPO stock but it gives an estimated listing price of the stock.
Sai Life Sciences, a Hyderabad-based contract research and manufacturing services (CRAMS) provider, aims to raise ₹3,042.62 crore through its IPO. The total offer size is a combination of a fresh issue of shares worth ₹950 crore and an offer-for-sale (OFS) portion of ₹2,092.62 crore.
The IPO price band has been fixed at ₹522-549 per share. The minimum investment for the retail investors is ₹14,823 for at least a single lot size of 27 shares.
The IPO allotment status is expected to be finalised by Sai Life Sciences on December 16. Shares of Sai Life Sciences Ltd will make their debut on the stock exchanges on December 18.
Sai Life Sciences specialises in offering end-to-end solutions for small molecule drug development and manufacturing, serving global pharmaceutical and biotech companies. The company reported a net profit of ₹28.01 crore in the six months ended September 2024, marking a turnaround from a net loss in the previous year.
Sai Life Sciences offers exposure to the growing pharmaceutical CRAMS sector, driven by global demand for innovative drug solutions.
First Published: Dec 11, 2024 4:32 PM IST
Live TV
Loading...
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!